Yvedt L. Matory

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1985 · 2.6K citations

Medicine, Immunology, Oncology +15

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Michael T. Lotze, Yvedt L. Matory, Stephen E. Ettinghausen et al. · The Journal of Immunology · 1985 · 614 citations

Life Sciences, Immunology, Pharmacology +9

Clinical effects and toxicity of interleukin-2 in patients with cancer

Michael T. Lotze, Yvedt L. Matory, Anthony A. Rayner et al. · Cancer · 1986 · 358 citations · Full text

Life Sciences, Immunology, Oncology +13

Magnetic Resonance Imaging Versus Computed Tomography in the Evaluation of Soft Tissue Tumors of the Extremities

Alfred E. Chang, Yvedt L. Matory, Andrew J. Dwyer et al. · Annals of Surgery · 1987 · 148 citations

Medicine, Oncology, Radiology +17

Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

Yvedt L. Matory, Alfred E. Chang, Edward H. Lipford et al. · PubMed · 1985 · 55 citations

Medicine, Immunology, Pharmacology +10